Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing
T-CURX and Pantherna are combining CAR-T, mRNA and LNP platforms. Europe’s in vivo cell therapy race just became more serious.
PeproMene Bio’s EHA 2026 data spotlight BAFF-R CAR T in relapsed lymphoma
PeproMene Bio’s PMB-CT01 data raise fresh questions for post-CD19 CAR T lymphoma care. Find out what the early signal means.
How NewcelX Ltd. is pursuing durable islet graft survival in the race for a functional diabetes cure
How NewcelX Ltd. is advancing NCEL-101 toward a functional diabetes cure through durable islet graft survival and immune protection strategies.
Can FUJIFILM’s Madison facility help solve the scale problem in stem cell manufacturing?
iPSC demand is rising fast. FUJIFILM’s Madison facility tests whether stem cell manufacturing can keep pace with pharma and cell therapy needs.
Charles River and MEDIPOST deepen cell therapy testing push across APAC and North America
Cell therapy scale-up is not just a science problem. Charles River and MEDIPOST are targeting the GMP testing bottleneck.
Can Cellular Intelligence revive Novo Nordisk’s shelved Parkinson’s cell therapy programme?
Novo shelved the asset, but Cellular Intelligence sees a platform test. Parkinson’s cell therapy now faces its harder commercial trial.
Could Therorna’s circRNA in vivo CAR-T platform change autoimmune disease treatment?
CAR-T is powerful but hard to scale. Therorna’s circRNA platform tests whether in vivo engineering can move the field beyond bespoke therapy.
How Imviva Biotech is positioning allogeneic CAR-T therapy for autoimmune disease disruption
Can CTA313 redefine lupus treatment with CAR-T? Explore what Imviva Biotech’s early data means for autoimmune therapy innovation.
Tempest Therapeutics, Inc. bets on dual-targeting CAR-T to address antigen escape challenges
Tempest Therapeutics, Inc. advances TPST-2003 CAR-T data. Discover how dual-targeting could impact multiple myeloma treatment durability.
Obsidian Therapeutics puts OBX-115 in the spotlight, but is this a real melanoma cell therapy inflection point?
Obsidian Therapeutics will present OBX-115 melanoma data at ASCO 2026. Read why the update matters for TIL therapy, scalability, and solid tumor strategy.